Assessment of Neonatal Intensive Care Unit Practices and Preterm Newborn Gut Microbiota and 2-Year Neurodevelopmental Outcomes.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 09 2020
Historique:
entrez: 23 9 2020
pubmed: 24 9 2020
medline: 14 1 2021
Statut: epublish

Résumé

In very preterm newborns, gut microbiota is highly variable with major dysbiosis. Its association with short-term health is widely studied, but the association with long-term outcomes remains unknown. To investigate in preterm newborns the associations among practice strategies in neonatal intensive care units (NICUs), gut microbiota, and outcomes at 2 years. EPIFLORE is a prospective observational cohort study that includes a stool sample collection during the fourth week after birth. Preterm newborns of less than 32 weeks of gestational age (GA) born in 2011 were included from 24 NICUs as part of the French nationwide population-based cohort, EPIPAGE 2. Data were collected from May 2011 to December 2011 and analyzed from September 2016 to December 2018. Eight NICU strategies concerning sedation, ventilation, skin-to-skin practice, antibiotherapy, ductus arteriosus, and breastfeeding were assessed. A NICU was considered favorable to a practice if the percentage of that practice in the NICU was more than the expected percentage. Gut microbiota was analyzed by 16S ribosomal RNA gene sequencing and characterized by a clustering-based method. The 2-year outcome was defined by death or neurodevelopmental delay using a Global Ages and Stages questionnaire score. Of 577 newborns included in the study, the mean (SD) GA was 28.3 (2.0) weeks, and 303 (52.5%) were male. Collected gut microbiota was grouped into 5 discrete clusters. A sixth cluster included nonamplifiable samples owing to low bacterial load. Cluster 4 (driven by Enterococcus [n = 63]), cluster 5 (driven by Staphylococcus [n = 52]), and cluster 6 (n = 93) were significantly associated with lower mean (SD) GA (26.7 [1.8] weeks and 26.8 [1.9] weeks, respectively) and cluster 3 (driven by Escherichia/Shigella [n = 61]) with higher mean (SD) GA (29.4 [1.6] weeks; P = .001). Cluster 3 was considered the reference. After adjustment for confounders, no assisted ventilation at day 1 was associated with a decreased risk of belonging to cluster 5 or cluster 6 (adjusted odds ratio [AOR], 0.21 [95% CI, 0.06-0.78] and 0.19 [95% CI, 0.06-0.62], respectively) when sedation (AOR, 10.55 [95% CI, 2.28-48.87] and 4.62 [1.32-16.18], respectively) and low volume of enteral nutrition (AOR, 10.48 [95% CI, 2.48-44.29] and 7.28 [95% CI, 2.03-26.18], respectively) was associated with an increased risk. Skin-to-skin practice was associated with a decreased risk of being in cluster 5 (AOR, 0.14 [95% CI, 0.04-0.48]). Moreover, clusters 4, 5, 6 were significantly associated with 2-year nonoptimal outcome (AOR, 6.17 [95% CI, 1.46-26.0]; AOR, 4.53 [95% CI, 1.02-20.1]; and AOR, 5.42 [95% CI, 1.36-21.6], respectively). Gut microbiota of very preterm newborns at week 4 is associated with NICU practices and 2-year outcomes. Microbiota could be a noninvasive biomarker of immaturity.

Identifiants

pubmed: 32965499
pii: 2770943
doi: 10.1001/jamanetworkopen.2020.18119
pmc: PMC7512059
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2018119

Références

Matern Health Neonatol Perinatol. 2015 Feb 11;1:6
pubmed: 27057323
Sci Rep. 2018 Feb 6;8(1):2453
pubmed: 29410448
Adv Neonatal Care. 2015 Oct;15(5):324-35
pubmed: 26340035
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Microbiome. 2016 Dec 29;4(1):67
pubmed: 28034304
Am J Clin Nutr. 2017 Sep;106(3):821-830
pubmed: 28659297
Arch Dis Child Fetal Neonatal Ed. 2014 Sep;99(5):F366-72
pubmed: 24916576
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12522-7
pubmed: 25114261
Birth Defects Res C Embryo Today. 2015 Dec;105(4):252-64
pubmed: 26663857
Nucleic Acids Res. 2009 Jan;37(Database issue):D141-5
pubmed: 19004872
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Nat Commun. 2016 Jun 24;7:11939
pubmed: 27340092
Microbiome. 2014 Oct 01;2:36
pubmed: 25332767
JAMA. 2015 Jun 23-30;313(24):2441-8
pubmed: 26103028
Clin Perinatol. 2019 Mar;46(1):29-38
pubmed: 30771817
J Clin Microbiol. 1990 Sep;28(9):1942-6
pubmed: 2095137
Lancet Respir Med. 2016 Jan;4(1):59-72
pubmed: 26700442
Microbiome. 2018 Jun 20;6(1):112
pubmed: 29925423
Microbiome. 2014 Oct 13;2:38
pubmed: 25332768
BMJ. 2017 Aug 16;358:j3448
pubmed: 28814566
J Pediatr Gastroenterol Nutr. 2016 Feb;62(2):292-303
pubmed: 26230901
Dev Cogn Neurosci. 2019 Jun;37:100627
pubmed: 30981894
JAMA Pediatr. 2015 Mar;169(3):230-8
pubmed: 25621457
Nat Commun. 2019 Feb 27;10(1):968
pubmed: 30814504
Ann Clin Microbiol Antimicrob. 2018 Mar 19;17(1):9
pubmed: 29554907
mSystems. 2019 Feb 26;4(1):
pubmed: 30834328
Semin Fetal Neonatal Med. 2018 Dec;23(6):400-405
pubmed: 30172660
Nat Commun. 2017 Nov 27;8(1):1814
pubmed: 29180750
Microbiome. 2018 Sep 12;6(1):157
pubmed: 30208950
Nat Commun. 2019 Apr 3;10(1):1517
pubmed: 30944304
Nat Med. 2018 Apr 10;24(4):392-400
pubmed: 29634682
PLoS One. 2011;6(5):e20004
pubmed: 21637833
Front Cell Neurosci. 2017 Feb 07;11:25
pubmed: 28223922
Int J Epidemiol. 2018 Oct 1;47(5):1658-1669
pubmed: 29688458
J Pediatr Gastroenterol Nutr. 2007 May;44(5):577-82
pubmed: 17460489
Microbiome. 2017 Dec 11;5(1):158
pubmed: 29228972
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040

Auteurs

Jean-Christophe Rozé (JC)

Neonatal Department, INSERM-CHU Clinical Investigation Center 1413, et UMR- INRA 1280, Physiologie des Adaptations Nutritionnelles, Nantes University Hospital, Nantes, France.

Pierre-Yves Ancel (PY)

Université de Paris, Center for Epidemiology and Statistics/CRESS U1153/EPOPé Team, Paris, France.
Clinical Investigation Center P1419, Assistance Publique-Hôpitaux de Paris, Paris, France.

Laetitia Marchand-Martin (L)

Université de Paris, Center for Epidemiology and Statistics/CRESS U1153/EPOPé Team, Paris, France.

Clotilde Rousseau (C)

UMR-S INSERM U1139, Faculté de Pharmacie, Université de Paris, Paris, France.
PremUp Foundation, Paris, France.
Microbiology Department, AP-HP Hôpital Saint-Louis, Paris, France.

Emmanuel Montassier (E)

Service des Urgences, Nantes University Hospital, Nantes, France.

Céline Monot (C)

Micalis Institute, INRA, AgroParisTech, University Paris-Saclay, Paris, France.

Karine Le Roux (K)

Micalis Institute, INRA, AgroParisTech, University Paris-Saclay, Paris, France.

Marine Butin (M)

Neonatal Department, Hospices Civils de Lyon, Lyon, France.

Matthieu Resche-Rigon (M)

Biostatistics and Medical Information Department, AP-HP Hôpital Saint-Louis, Paris, France.

Julio Aires (J)

UMR-S INSERM U1139, Faculté de Pharmacie, Université de Paris, Paris, France.
PremUp Foundation, Paris, France.

Josef Neu (J)

College of Medicine, University of Florida, Gainesville, Florida.

Patricia Lepage (P)

Micalis Institute, INRA, AgroParisTech, University Paris-Saclay, Paris, France.

Marie-José Butel (MJ)

UMR-S INSERM U1139, Faculté de Pharmacie, Université de Paris, Paris, France.
PremUp Foundation, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH